
The nonhormonal neurokinin-3 receptor antagonist improved menopausal adiposity without appreciable impact on body weight or BMI, Santoro explained at 2025 ACOG meeting.

The nonhormonal neurokinin-3 receptor antagonist improved menopausal adiposity without appreciable impact on body weight or BMI, Santoro explained at 2025 ACOG meeting.

ACOG 2025: Pregnant patients may not want to discuss weight gain initially, so focus on overall perinatal health, and use that information to guide more conversation.

Your daily dose of the clinical news you may have missed.

LeThenia Joy Baker, MD, explains why PPD is often overlooked compared to physical pregnancy conditions like gestational diabetes.

An intervention that included educational materials for clinicians on a multidisciplinary prenatal and postpartum care team helped drive acceptance.

Pregnant patients' perceptions do not match clinician certainty on abstinence counseling during pregnancy, and clinicians may not be asking patients about their partner's substance use.

Researchers report an alarming number of missed opportunities to screen pregnant individuals for thyroid disease, including among women with a history of the condition.

ACOG 2025: Dr Baker shares how language can help create a trusting space for patients to speak openly about postpartum depression.

ACOG 2025: Joy Baker, MD, called for stronger cross-specialty collaboration to address maternal mental health after birth.

Steven Fleischman, MD, was inaugurated as ACOG’s 76th president, urging new fellows to lead with purpose and recognize their value in women’s health care.

The diagnostic is designed to help clinicians determine the likelihood of cerebral β-amyloid plaque deposition, one of the neuropathologic hallmarks of AD.

Fewer than half of females who experienced heavy menstrual bleeding were given hormonal treatment, and far fewer were referred to gynecology, authors reported.

The findings support the potential cardiovascular advantages of the GLP-1RA class in women with PCOS, a population already at increased cardiometabolic risk.

While exercise is beneficial during pregnancy and ACOG recommends 150 mins/week, this is the first study to examine benefits of specific regimen elements on their own.

Postmenopausal women taking fezolinetant experienced positive changes in body fat distribution, increases in which are known to increase risks of cardiometabolic disease.

Elinzanetant reduced VMS frequency and intensity, and improved sleep and quality of life, according to the meta-analysis to be presented at the ACOG 2025 meeting.


The two areas where primary care physicians can contribute to improving women's health, according to Laurence Shields, MD.
Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.
